PMID- 34054859
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance.
PG  - 674048
LID - 10.3389/fimmu.2021.674048 [doi]
LID - 674048
AB  - Dendritic cells (DCs) are paramount in initiating and guiding immunity towards a 
      state of activation or tolerance. This bidirectional capacity of DCs sets them at 
      the center stage for treatment of cancer and autoimmune or allergic conditions. 
      Accordingly, many clinical studies use ex vivo DC vaccination as a strategy to 
      boost anti-tumor immunity or to suppress immunity by including vitamin D3, NF-kappaB 
      inhibitors or retinoic acid to create tolerogenic DCs. As harvesting DCs from 
      patients and differentiating these cells in vitro is a costly and cumbersome 
      process, in vivo targeting of DCs has huge potential as nanoparticulate platforms 
      equipped with activating or tolerogenic adjuvants can modulate DCs in their 
      natural environment. There is a rapid expansion of the choices of nanoparticles 
      and activation- or tolerance-promoting adjuvants for a therapeutic vaccine 
      platform. In this review we highlight the most recent nanomedical approaches 
      aimed at inducing immune activation or tolerance via targeting DCs, together with 
      novel fundamental insights into the mechanisms inherent to fostering anti-tumor 
      or tolerogenic immunity.
CI  - Copyright (c) 2021 Nagy, de Haas, Geijtenbeek, van Ree, Tas, van Kooyk and de Jong.
FAU - Nagy, Noemi Anna
AU  - Nagy NA
AD  - Department of Experimental Immunology, Amsterdam University Medical Center, 
      Amsterdam Institute for Infection and Immunity, University of Amsterdam, 
      Amsterdam, Netherlands.
FAU - de Haas, Aram M
AU  - de Haas AM
AD  - Department of Molecular Cell Biology and Immunology, Amsterdam University Medical 
      Center, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, 
      Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
FAU - Geijtenbeek, Teunis B H
AU  - Geijtenbeek TBH
AD  - Department of Experimental Immunology, Amsterdam University Medical Center, 
      Amsterdam Institute for Infection and Immunity, University of Amsterdam, 
      Amsterdam, Netherlands.
FAU - van Ree, Ronald
AU  - van Ree R
AD  - Department of Experimental Immunology, Amsterdam University Medical Center, 
      Amsterdam Institute for Infection and Immunity, University of Amsterdam, 
      Amsterdam, Netherlands.
AD  - Department of Otorhinolaryngology, Amsterdam University Medical Center, 
      University of Amsterdam, Amsterdam, Netherlands.
FAU - Tas, Sander W
AU  - Tas SW
AD  - Department of Experimental Immunology, Amsterdam University Medical Center, 
      Amsterdam Institute for Infection and Immunity, University of Amsterdam, 
      Amsterdam, Netherlands.
AD  - Department of Rheumatology and Clinical Immunology, Amsterdam University Medical 
      Center, Amsterdam Rheumatology and Immunology Center, University of Amsterdam, 
      Amsterdam, Netherlands.
FAU - van Kooyk, Yvette
AU  - van Kooyk Y
AD  - Department of Molecular Cell Biology and Immunology, Amsterdam University Medical 
      Center, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, 
      Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
FAU - de Jong, Esther C
AU  - de Jong EC
AD  - Department of Experimental Immunology, Amsterdam University Medical Center, 
      Amsterdam Institute for Infection and Immunity, University of Amsterdam, 
      Amsterdam, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210513
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Liposomes)
RN  - 0 (Vaccines)
SB  - IM
MH  - Dendritic Cells/*immunology
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Immune Tolerance/*immunology
MH  - *Liposomes/chemistry/immunology
MH  - *Nanoparticles/chemistry
MH  - *Vaccines/chemistry/immunology
PMC - PMC8155586
OTO - NOTNLM
OT  - activation
OT  - adjuvant
OT  - antigen
OT  - dendritic cell (DC)
OT  - liposomes
OT  - nanoparticle
OT  - targeting
OT  - tolerance
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/06/01 06:00
MHDA- 2021/10/16 06:00
PMCR- 2021/05/13
CRDT- 2021/05/31 06:08
PHST- 2021/02/28 00:00 [received]
PHST- 2021/04/26 00:00 [accepted]
PHST- 2021/05/31 06:08 [entrez]
PHST- 2021/06/01 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/05/13 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.674048 [doi]
PST - epublish
SO  - Front Immunol. 2021 May 13;12:674048. doi: 10.3389/fimmu.2021.674048. eCollection 
      2021.